Trial | NCT00273442  Report issue

Title

Assessing Cosopt Switch Patients

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    dorzolamide timolol ...

  • Study Participants

    60
To assess the safety and efficacy of a cohort of patients switched to the dorzolamide/timolol maleate fixed combination because they are insufficiently controlled on latanoprost monotherapy.
Study Started
Nov 30
2005
Study Completion
Apr 30
2007
Last Update
Nov 19
2008
Estimate

Drug timolol maleate

Drug dorzolamide/timolol maleate fixed combination

Criteria 

Inclusion Criteria:

adults with clinical diagnosis of POAG, pigment-dispersion or exfoliation glaucoma or ocular hypertension
the IOP on latanoprost must be 31 mm Hg or less in both eyes, and 21 to 31 mm Hg inclusive in at least one eye at 08:00 AM
visual acuity should be 20/200 or better in each eye

Exclusion Criteria:

contraindications to study drugs
anticipated change in systemic hypotensive therapy during the trial
use of any corticosteroids by any route in the three months immediately prior to Visit 2
No Results Posted